Prescribing Patterns of Antibiotics for the Self-Treatment of Travelers’ Diarrhea in Global TravEpiNet, 2009–2018

Aditya R. Gandhi,1,2 Sowmya R. Rao,3 Lin H. Chen,4 Michael D. Nelson,4 Edward T. Ryan,5 Regina C. LaRocque,5 Emily P. Hyle1

1Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, Massachusetts, USA, 2Biostatistics Center, Massachusetts General Hospital, Boston, Massachusetts, USA, 3Department of Global Health, Boston University School of Public Health, Boston, Massachusetts, USA, 4Travel Medicine Center, Mount Auburn Hospital, Cambridge, Massachusetts, USA, 5Harvard Medical School, Boston, Massachusetts, USA, 6Travelers’ Advice and Immunization Center, Massachusetts General Hospital, Boston, Massachusetts, USA, 7Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA, 8Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA, and 9Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA

Background. International travelers are often prescribed antibiotics for self-treatment of travelers’ diarrhea (TD), but the benefits and risks of antibiotics are debated. We assessed the prescribing patterns of empiric antibiotics for TD in international travelers evaluated at Global TravEpiNet (GTEN) sites (2009–2018).

Methods. We performed a prospective, multisite cross-sectional study regarding antibiotic prescriptions for the self-treatment of TD at 31 GTEN sites providing pretravel consultations to adult international travelers. We described traveler demographics, itineraries, and antibiotic(s) prescribed. We used multivariable logistic regressions to assess the association of year of consultation with antibiotic prescribing (yes/no) and class (fluoroquinolones vs azithromycin). We performed interrupted time-series analyses to examine differences in prescribing before and after the Food and Drug Administration (FDA) warning on fluoroquinolones (July 2016).

Results. Antibiotics were not prescribed in 23 096 (22.2%) of 103 843 eligible pretravel GTEN consultations; azithromycin and fluoroquinolones were most frequently prescribed. Antibiotic prescribing declined significantly each year between 2009 and 2018 (odds ratio [OR], 0.84; 95% CI, 0.79–0.89), as did fluoroquinolone prescribing, relative to azithromycin (OR, 0.77; 95% CI, 0.73–0.82). The rate of decline in fluoroquinolone prescribing was significantly greater after the FDA fluoroquinolone warning (15.3%/year) than before (1.1%/year; P < .001).

Conclusions. Empiric antibiotics for TD were prescribed in >75% of pretravel GTEN consultations, but antibiotic prescribing declined steadily between 2009 and 2018. Fluoroquinolones were less frequently prescribed than azithromycin, especially after the 2016 FDA fluoroquinolone warning. Emphasis on the risks of antibiotics may influence antibiotic prescribing by providers for empiric treatment of TD.

Keywords. antibiotics; drug resistance; fluoroquinolones; travelers’ diarrhea.

Travelers’ diarrhea (TD) is the most common illness experienced during international travel, affecting 10%–60% of all travelers [1, 2]. Antibiotics, including azithromycin and fluoroquinolones, are active against common bacterial etiologies of TD and are frequently prescribed to international travelers for the empiric self-treatment of diarrhea [1]. Antibiotic self-treatment can lead to rapid recovery from TD, thereby minimizing disruptions to itineraries. It may also prevent postinfectious irritable bowel syndrome, which has been associated with prolonged and severe cases of TD [3, 4]. Although TD is common, many cases are mild and can usually be treated with supportive care alone [1, 4–6]. A recent systematic review found that loperamide may have efficacy similar to that of antibiotics in treating mild or moderate TD [7], and the combination of loperamide and antibiotics is the most effective [8, 9]. Because the severity of TD can vary widely, pretravel antibiotic prescribing for the self-treatment of TD is common practice [1, 6].

Antibiotics have risks that may be underestimated by both providers and patients. Antibiotic therapy has been associated with adverse events including *Clostridium difficile* infection and QTc prolongation [10, 11]. The overuse of antibiotics has led to increasing antimicrobial resistance, an emerging public health concern [12, 13]. International travel itself is a risk factor for the acquisition of organisms with high antimicrobial resistance that can be transmitted upon return, leading some to call for greater antimicrobial stewardship efforts specifically targeted at international travelers [14–17]. In view of these factors, the International Society for Travel Medicine (ISTM) released new guidelines in 2017 recommending supportive care in lieu of antibiotic treatment for mild or “nondistressing” TD, with antibiotics recommended for moderate TD (weak recommendation) and severe TD (strong recommendation) [6].
Fluoroquinolones, in particular, have been linked to serious adverse events. In 2016, the Food and Drug Administration (FDA) released a warning regarding “disabling and potentially permanent” musculoskeletal and central nervous system adverse events associated with fluoroquinolones and has subsequently released 2 additional warnings, further highlighting the risk of fluoroquinolone-related neuropsychiatric toxicity, aortic dissection, and long-term disability [18–21]. Although TD is not explicitly cited in the FDA warnings, fluoroquinolone antibiotics are no longer recommended for nonserious bacterial infections such as uncomplicated urinary tract infections [18].

Surveillance data demonstrate that bacterial pathogens associated with TD are increasingly resistant to fluoroquinolones. Campylobacter species comprise 15%–20% of TD etiologies in Southeast Asia, and fluoroquinolone resistance has reached 70%–80% in Campylobacter isolates from that region [2, 22–24]. In such settings, travelers who take fluoroquinolones for TD could be exposed to adverse events without clinical benefit. The 2017 ISTM guidelines explicitly recommended against prescribing fluoroquinolones to travelers visiting Southeast Asia [6]. Moreover, these guidelines also recommended azithromycin as first-line antimicrobial therapy for severe TD [6].

In this analysis, we first sought to describe antibiotic prescribing patterns for the self-treatment of TD for adult international travelers from 2009 through 2018. We next examined for associations between demographics and travel-related characteristics and the prescription of any antibiotic and, in particular, prescriptions for fluoroquinolones relative to azithromycin. Finally, we assessed time trends for antibiotic and fluoroquinolone prescribing over the study period.

METHODS

Study Setting
Global TravEpiNet (GTEN) is a Centers for Disease Control and Prevention (CDC)–sponsored consortium of clinics that provide pretravel health consultations. GTEN sites are geographically dispersed in the United States across the 4 Census regions: Northeast (9 sites), Midwest (3 sites), South (11 sites), and West (8 sites). The consortium is comprised of 20 academic centers (ie, affiliated with university hospitals or medical schools) and 11 nonacademic centers (7 public health clinics, 2 primary care clinics, 1 health network, and 1 pharmacy).

Study Population and Eligibility Criteria
We examined trends in antibiotic prescribing between January 12, 2009, and December 31, 2018. We excluded pretravel consultations in which travelers were younger than 18 years, reported an itinerary outside a World Health Organization (WHO)–defined region, received only prophylactic antibiotics, had an existing prescription or antibiotics from another provider, or indicated a travel time of 0 days or >2000 days.

Data Collection: Traveler Demographics, Travel-Related Characteristics, and Categorization of Antibiotic Prescribing
Data were prospectively collected at GTEN sites using a standardized online questionnaire completed by the traveler and provider. Travelers provided demographic information, including age, sex, self-reported medical history and allergies, and details regarding travel itinerary such as reason for travel, destination(s), and duration of travel. Providers confirmed these data and entered the vaccinations recommended and administered at the pretravel consultation, medications prescribed, and health advice discussed during the visit [25].

We categorized travelers by sex (male or female), age (ie, 18–49 years, 50–64 years, and ≥65 years), and self-reported drug allergies. We categorized travel destination into 6 WHO-defined regions [26]. Itineraries that included countries in >1 WHO region contributed data to multiple regions. Travelers specified their reason(s) for travel, which we categorized into 6 mutually exclusive categories in the following rank order: visiting friends and relatives (VFR), business, humanitarian service (including providing medical care, nonmedical service work, and missionary work), research/education, leisure, and other [25]. For example, travelers who selected both VFR and leisure contributed only to the VFR category. We categorized duration of travel into 3 groups: <14 days, 14–29 days, and ≥30 days.

We first categorized pretravel consultations by antibiotic prescribing (yes/no). We further categorized antibiotic prescribing into classes: azithromycin only, fluoroquinolone only, rifaximin only, other antibiotic only, and >1 antibiotic. Travelers receiving only doxycycline as malaria prophylaxis were categorized as receiving no antibiotics for TD.

Statistical Analyses
We obtained distributions of demographic and travel-related characteristics stratified by the categories of antibiotic prescribing used in this analysis. We obtained odds ratios (ORs) and 95% CIs from univariate and multivariable logistic regressions to assess the association of demographics, travel-related characteristics, and linear trends over time with (1) prescribing of any antibiotics compared with no antibiotics and (2) prescribing of fluoroquinolones compared with azithromycin. We considered the survey year of evaluation as a continuous variable to observe changes over the entire study period. We also performed interrupted time-series (ITS) analysis to examine fluoroquinolone prescribing practices before and after the FDA warning on fluoroquinolones (July 2016). From the ITS analysis, we estimated the effect of the intervention (the FDA warning) by comparing the trends in antibiotic prescribing before and after the intervention. We conducted our analyses using SAS, version 9.4 (SAS Institute Inc., Cary, NC, USA), and SUDAAN 11.0.3 (RTI International, Durham, NC, USA) and considered a 2-sided P value <.05 to be significant.
IRB Approval
An institutional review board at all 31 participating sites either approved the study or considered it exempt from review.

Patient Consent Statement
We obtained institutional review board (IRB) approval at all participating GTEN sites; IRBs at each participating clinical site waived the need for written or oral informed consent because the study collected only deidentified data routinely collected during a standard clinical encounter.

RESULTS
Study Population
There were 121,295 pretravel consultations at participating GTEN sites between January 12, 2009, and December 31, 2018. We excluded 17,452 consultations for the reasons described above and included the remaining 103,843 pretravel consultations in this analysis (Figure 1).

Cohort Demographics
Among 103,843 eligible pretravel consultations, 45,282 travelers were male (43.6%), and 11,745 travelers (11.3%) were over age 65. Most travelers reported no drug allergies (79,724 [76.8%]); 626 (<1%) reported allergies to fluoroquinolones only, 1,283 (1.2%) reported allergies to macrolides only, and 52 (<1%) had allergies to both fluoroquinolones and macrolides. The most common destination region was Africa, followed by the Americas and Southeast Asia. Most travelers were planning itineraries for <14 days (43,868 [42.2%]) or 14–29 days (41,083 [39.6%]), and most were traveling for leisure (49,928 [48.1%]). Only 7,527 (7.2%) travelers met criteria for VFR. Academic centers accounted for 87,975 (84.7%) of eligible pretravel consultations (Table 1).

Antibiotics Prescribed During Pretravel Consultations
Providers did not prescribe antibiotics in 23,096 (22.2%) pretravel consultations but did in 80,747 (77.8%) pretravel consultations (Figure 1). Among all pretravel consultations at GTEN sites, antibiotics prescribed included azithromycin only (42,697 [41.1%]), fluoroquinolone only (36,248 [34.9%]), rifaximin only (740 [<1%]), another antibiotic only (11 [<1%]), and >1 antibiotic (1,051 [1.0%]) (Supplementary Table 1).

Predictors of Antibiotic Prescribing
Providers at GTEN sites were more likely to prescribe antibiotics for TD if travelers were 50–64 years old, reported an allergy to fluoroquinolones, were traveling to Southeast Asia or the Western Pacific, or were evaluated at an academic center. Providers were less likely to prescribe antibiotics to travelers who were traveling for ≥30 days, were VFR travelers, or were evaluated at GTEN clinics in the South (Table 2).

Figure 1. Flow diagram of travel encounters at GTEN sites (2009–2018). Between 2009 and 2018, 121,295 pretravel consultations were recorded at GTEN sites, of which 103,843 met the inclusion criteria of the study. Providers prescribed antibiotics for empiric treatment of TD in 80,747 pretravel consultations, of which 1,051 received >1 antibiotic. The combinations of >1 antibiotic include azithromycin and fluoroquinolone (n = 825); azithromycin and rifaximin (n = 148); fluoroquinolone and rifaximin (n = 39); fluoroquinolone and other (n = 22); azithromycin and other (n = 9); fluoroquinolone, azithromycin, and rifaximin (n = 5); and fluoroquinolone, azithromycin, and other (n = 3). The other category included prescriptions for metronidazole, doxycycline, trimethoprim-sulfamethoxazole, and amoxicillin-clavulanate for travelers’ diarrhea self-treatment and/or other nonmalaria prophylaxis indications (eg, respiratory infection, UTI). Abbreviations: GTEN, Global TravEpiNet; TD, travelers’ diarrhea; UTI, urinary tract infection; WHO, World Health Organization; WHO-defined regions: Africa, Americas, Southeast Asia, Europe, Eastern Mediterranean, Western Pacific.
When adjusting for demographic and travel-related predictors, a significant decline in antibiotic prescribing was observed over the study period (OR, 0.84; 95% CI, 0.79–0.89) (Table 2): from 92% of pretravel consultations in 2009 to 70% in 2018 (Figure 2A). The ITS analyses revealed no significant change in the rate of decline in antibiotic prescribing due to the intervention (ie, the FDA warning or ISTM guidelines).

### Predictors of Fluoroquinolone Prescribing Compared With Azithromycin Prescribing

Relative to azithromycin prescribing, fluoroquinolone prescribing was associated with travel to Africa, the Americas, Europe, or the Eastern Mediterranean. Providers were more likely to prescribe fluoroquinolones to travelers age 50–64 and were less likely to prescribe fluoroquinolones to travelers who were female, had a fluoroquinolone allergy, were traveling to Southeast Asia or the Western Pacific, or were evaluated at a GTEN clinic in the Midwest (Table 3). Among female travelers, fluoroquinolones were more likely to be prescribed to those age ≥50 years compared with females of childbearing age (18–49 years), after adjusting for other variables (OR, 1.42; 95% CI, 1.06–1.89). Similar predictors of fluoroquinolone prescribing, in addition to travel for business, were observed among travelers to Southeast Asia (Supplementary Table 2).

### Table 1. Demographics and Travel-Related Characteristics of Adult Travelers Evaluated at GTEN Sites (2009–2018)

| Characteristics                                      | No. (n = 103,843) | Not Prescribed Antibiotics (n = 23,096) | Prescribed Antibiotics (n = 80,747) |
|------------------------------------------------------|-------------------|----------------------------------------|-------------------------------------|
| Sex, No. (row %)                                     |                   |                                        |                                     |
| Male                                                 | 45,282            | 9,836 (21.7)                           | 35,446 (78.3)                       |
| Female                                               | 58,561            | 13,260 (22.6)                          | 45,301 (77.4)                       |
| Age, No. (row %)                                     |                   |                                        |                                     |
| 18–49 y                                              | 68,440            | 15,091 (22.0)                          | 53,349 (78.0)                       |
| 50–64 y                                              | 23,658            | 5,263 (22.2)                           | 18,395 (77.8)                       |
| ≥65 y                                                | 11,745            | 2,742 (23.3)                           | 9,003 (76.7)                        |
| Drug allergies, No. (row %)                          |                   |                                        |                                     |
| No allergies                                         | 79,724            | 18,346 (23.0)                          | 61,378 (77.0)                       |
| FQ only                                              | 626               | 93 (14.9)                              | 533 (85.1)                          |
| Macrolide only                                       | 1,283             | 221 (17.2)                             | 1,062 (82.8)                        |
| FQ and macrolide                                     | 52                | 15 (28.8)                              | 37 (71.2)                           |
| Other antibiotic allergy                             | 22,158            | 4,421 (20.0)                           | 17,737 (80.0)                       |
| Duration of travel, No. (row %)                      |                   |                                        |                                     |
| <14 d                                                | 43,868            | 8,630 (19.7)                           | 35,238 (80.3)                       |
| 14–29 d                                              | 41,083            | 7,845 (19.1)                           | 33,238 (80.9)                       |
| ≥30 d                                                | 18,892            | 6,621 (35.0)                           | 12,271 (65.0)                       |
| Region of travel, No. (row %)                        |                   |                                        |                                     |
| Africa                                               | 37,604            | 10,804 (28.7)                          | 26,800 (71.3)                       |
| Americas                                             | 29,845            | 6,459 (21.6)                           | 23,386 (78.4)                       |
| Southeast Asia                                       | 24,612            | 3,169 (12.9)                           | 21,443 (87.1)                       |
| Western Pacific                                      | 18,872            | 2,977 (15.8)                           | 15,895 (84.2)                       |
| Europe                                               | 5,787             | 1,202 (20.8)                           | 4,585 (79.2)                        |
| Eastern Mediterranean                                | 5,653             | 1,434 (25.4)                           | 4,219 (74.6)                        |
| Reason for travel, No. (row %)                       |                   |                                        |                                     |
| Leisure                                              | 49,928            | 9,227 (18.5)                           | 40,701 (81.5)                       |
| Business                                             | 18,771            | 3,231 (17.2)                           | 15,540 (82.8)                       |
| Humanitarian service work                             | 15,315            | 3,704 (24.2)                           | 11,611 (75.8)                       |
| Research/education                                   | 7,784             | 1,537 (19.7)                           | 6,247 (80.3)                        |
| VFR                                                  | 7,527             | 3,250 (43.2)                           | 4,277 (56.8)                        |
| Other                                                 | 4,518             | 2,147 (47.5)                           | 2,371 (52.5)                        |
| US Census region of clinic site, No. (row %)          |                   |                                        |                                     |
| Northeast                                            | 45,817            | 5,927 (12.9)                           | 39,890 (87.1)                       |
| Midwest                                              | 8,506             | 572 (6.7)                              | 7,934 (93.3)                        |
| South                                                | 26,145            | 12,419 (47.5)                          | 13,726 (52.5)                       |
| West                                                 | 23,375            | 4,178 (17.9)                           | 19,197 (82.1)                       |
| Type of clinic, No. (row %)                           |                   |                                        |                                     |
| Nonacademic center                                    | 15,868            | 10,169 (64.1)                          | 5,699 (35.9)                        |
| Academic center                                      | 87,975            | 12,927 (14.7)                          | 75,048 (85.3)                       |

Abbreviations: FQ, fluoroquinolone; GTEN, Global TravEpiNet; VFR, visiting friends and relatives.

*Travelers can contribute to >1 region.
Fluoroquinolone Prescribing Patterns From 2009 to 2018

Among all travelers, when adjusting for demographic and travel-related characteristics, fluoroquinolone prescriptions declined significantly each year from 2009 to 2018, compared with azithromycin prescriptions (OR, 0.77; 95% CI, 0.73–0.82) (Table 3). Notable decreases in any fluoroquinolone prescribing were observed between 2016 and 2018: from 57% in July 2016 (FDA warning) to 46% in March 2017 (ISTM guidelines), and to 17% in December 2018 (final survey year). When examining for changes in practices after the release of the FDA warning, fluoroquinolone prescriptions declined 1.1%/year before July 2016 ($p = .027$) and 15.3%/year thereafter ($p < .001$) (Figure 2B). The rate of decline after July 2016 was greater and significant compared with

---

Table 3. Results From Logistic Regressions Assessing the Relationship of Demographics and Travel Characteristics With Prescribing Antibiotics for TD Among Travelers Evaluated at GTEN Sites (2009–2018)

| Characteristics       | Unadjusted OR (95% CI) | Unadjusted $p$ Value | Adjusted OR (95% CI)$^a$ | Adjusted $p$ Value$^a$ |
|------------------------|------------------------|----------------------|--------------------------|------------------------|
| Sex                    |                        |                      |                          |                        |
| Male                   | Ref                    | .46                  | Ref                      | .77                    |
| Female                 | 0.95 (0.82–1.10)       |                      | 1.02 (0.89–1.18)          |                        |
| Age                    |                        |                      |                          |                        |
| 18–49 y                | Ref                    | .54                  | Ref                      | .045                   |
| 50–64 y                | 0.99 (0.77–1.26)       |                      | 1.14 (1.01–1.28)          |                        |
| ≥65 y                  | 0.93 (0.73–1.18)       |                      | 1.19 (0.92–1.54)          |                        |
| Drug allergies         |                        |                      |                          |                        |
| No allergies           | Ref                    | <.001                | Ref                      | <.001                  |
| FQ only                | 1.71 (1.36–2.16)       |                      | 1.67 (1.24–2.26)          |                        |
| Macrolide only         | 1.44 (1.01–2.05)       |                      | 1.12 (0.86–1.46)          |                        |
| FQ and macrolide       | 0.74 (0.41–1.31)       |                      | 0.75 (0.42–1.33)          |                        |
| Other antibiotic allergy| 1.20 (1.01–1.42)     |                      | 1.14 (1.00–1.31)          |                        |
| Duration of travel     |                        |                      |                          |                        |
| <14 d                  | Ref                    | <.001                | Ref                      | <.001                  |
| 14–29 d                | 1.04 (0.92–1.17)       |                      | 0.99 (0.89–1.10)          |                        |
| ≥30 d                  | 0.45 (0.31–0.66)       |                      | 0.47 (0.32–0.70)          |                        |
| Region of travel$^b$   |                        |                      |                          |                        |
| Africa                 | 0.57 (0.35–0.90)       | .013                 | 1.01 (0.81–1.27)          | .92                    |
| Americas               | 1.05 (0.72–1.54)       | .79                  | 0.95 (0.75–1.21)          | .68                    |
| Southeast Asia         | 2.27 (1.68–3.07)       | <.001                | 1.88 (1.50–2.35)          | <.001                  |
| Western Pacific        | 1.66 (1.14–2.41)       | .006                 | 1.43 (1.17–1.74)          | <.001                  |
| Europe                 | 1.10 (0.76–1.58)       | .61                  | 0.90 (0.72–1.13)          | .35                    |
| Eastern Mediterranean  | 0.83 (0.69–1.00)       | .046                 | 0.98 (0.82–1.16)          | .79                    |
| Reason for travel      |                        |                      |                          |                        |
| Leisure                | Ref                    | <.001                | Ref                      | <.001                  |
| Business               | 1.09 (0.78–1.52)       |                      | 1.03 (0.83–1.27)          |                        |
| Humanitarian service work| 0.71 (0.47–1.08)    |                      | 0.76 (0.56–1.04)          |                        |
| Research/education     | 0.92 (0.69–1.24)       |                      | 1.17 (0.86–1.60)          |                        |
| VFR                    | 0.30 (0.13–0.70)       |                      | 0.33 (0.13–0.84)          |                        |
| Other                  | 0.25 (0.13–0.49)       |                      | 0.41 (0.28–0.59)          |                        |
| US Census region of clinic site |          |                      |                          |                        |
| Northeast              | Ref                    | .011                 | Ref                      | <.001                  |
| Midwest                | 2.06 (0.61–6.98)       |                      | 1.52 (0.78–2.93)          |                        |
| South                  | 0.16 (0.03–0.99)       |                      | 0.28 (0.11–0.89)          |                        |
| West                   | 0.68 (0.21–2.27)       |                      | 0.79 (0.24–2.64)          |                        |
| Type of clinic         |                        |                      |                          |                        |
| Nonacademic center     | Ref                    | .014                 | Ref                      | .005                   |
| Academic center        | 10.36 (1.49–72.23)     |                      | 7.30 (1.72–30.86)         |                        |
| Survey year            |                        |                      |                          |                        |
| 2009                   | Ref                    | <.001                | Ref                      | <.001                  |
| Each year after 2009   | 0.88 (0.84–0.93)       |                      | 0.84 (0.79–0.89)          |                        |

Abbreviations: FQ, fluoroquinolone; GTEN, Global TravEpiNet; OR, odds ratio; TD, travelers’ diarrhea; VFR, visiting friends and relatives.

Adjustment results obtained from regressions that include all variables shown in the table.

Reference: not traveling to that specific region. Travelers can contribute to >1 region.
that before July 2016 (P < .001). Similar declines in fluoroquinolone prescribing were observed before and after the release of the ISTM guidelines in March 2017 (before ISTM: 1.3%/year; P = .002; after ISTM: 13.6%/year; P < .001); when compared, the rates of decline were significantly different (P = .002). As fluoroquinolone prescribing declined significantly over the study period, azithromycin prescribing increased significantly.

A dramatic decline was observed in fluoroquinolone prescribing to Southeast Asia travelers: from 36% in 2009 to 4% in 2018 (Supplementary Figure 1A), which was significant after adjusting for demographic and travel-related characteristics (OR, 0.77; 95% CI, 0.71–0.83) (Supplementary Table 2). Fluoroquinolone prescribing declined 3.9%/year before July 2016 (P < .001) and 2.6%/year thereafter (P = .32) (Supplementary Figure 1B). Comparison of the rates of decline found no statistically significant difference (P = .65).

**DISCUSSION**

Providers prescribed antibiotics for the self-treatment of TD at >75% of GTEN pretravel consultations between 2009 and 2018. However, empiric antibiotic prescribing by providers declined significantly over the past 10 years (OR, 0.84; 95% CI, 0.79–0.89). Fluoroquinolone prescriptions, in particular, declined significantly between 2009 and 2018, whereas azithromycin prescriptions increased, especially for travelers visiting Southeast Asia.

The changes in observed prescribing practices may reflect ongoing efforts to reduce antibiotic adverse events and curb antimicrobial resistance by reducing antibiotic prescriptions for nonserious infections, such as mild TD. Such efforts include...
policy changes like the 2016 FDA warning on fluoroquinolones and 2017 ISTM guidelines on the empiric treatment of TD. We found a consistent decline in any TD antibiotic prescribing among GTEN travelers over the past 10 years, but ITS analysis did not reveal significant changes in prescribing trends before and after these 2 policy interventions. As new data regarding the risks and benefits of antibiotics emerge, pretravel providers play an important role in reducing antibiotic overuse to decrease the selective pressure for antimicrobial-resistant organisms among international travelers, a key at-risk population [14, 16, 17, 27]. As empiric antibiotic prescribing for TD remains common practice, providers must educate travelers about the risks and benefits of antibiotics and ISTM guideline-concordant management of TD (eg, recommending loperamide

| Characteristics           | Unadjusted OR (95% CI) | Unadjusted PValue | Adjusted OR (95% CI)* | Adjusted PValue* |
|---------------------------|------------------------|-------------------|-----------------------|------------------|
| Sex                       |                        |                   |                       |                  |
| Male                       | Ref                    | .47               | Ref                   | <.001            |
| Female                     | 1.02 (0.96–1.10)        |                   | 0.94 (0.92–0.96)      |                  |
| Age                        |                        |                   |                       |                  |
| 18–49 y                    | Ref                    | .063              | Ref                   | <.001            |
| 50–64 y                    | 1.22 (0.93–1.60)        |                   | 1.34 (1.08–1.66)      |                  |
| ≥65 y                      | 1.16 (0.84–1.62)        |                   | 1.29 (0.86–1.94)      |                  |
| Drug allergies             |                        |                   |                       |                  |
| No allergies               | Ref                    | <.001             | Ref                   | <.001            |
| FQ only                    | 0.08 (0.06–0.11)        |                   | 0.04 (0.03–0.06)      |                  |
| Macrolide only             | 4.53 (3.56–5.77)        |                   | 7.68 (5.69–10.54)     |                  |
| FQ and macrolide           | 0.74 (0.33–1.66)        |                   | 0.41 (0.12–1.40)      |                  |
| Other antibiotic allergy   | 1.04 (0.91–1.19)        |                   | 1.02 (0.96–1.08)      |                  |
| Duration of travel         |                        |                   |                       |                  |
| <14 d                      | Ref                    | .005              | Ref                   | .002             |
| 14–29 d                    | 0.76 (0.62–0.93)        |                   | 0.91 (0.85–0.97)      |                  |
| ≥30 d                      | 0.79 (0.65–0.95)        |                   | 0.97 (0.85–1.10)      |                  |
| Region of travelb          |                        |                   |                       |                  |
| Africa                     | 2.28 (1.62–3.19)        | <.001             | 1.97 (1.31–2.95)      | <.001            |
| Americas                   | 2.04 (1.44–2.90)        | <.001             | 1.74 (1.22–2.48)      | .002             |
| Southeast Asia             | 0.15 (0.07–0.34)        | <.001             | 0.17 (0.07–0.40)      | <.001            |
| Western Pacific            | 0.37 (0.27–0.50)        | <.001             | 0.44 (0.38–0.51)      | <.001            |
| Europe                     | 1.17 (1.02–1.35)        | .019              | 1.22 (1.07–1.40)      | .003             |
| Eastern Mediterranean      | 1.03 (0.90–1.18)        | .63               | 1.20 (1.03–1.40)      | .017             |
| Reason for travel          |                        |                   |                       |                  |
| Leisure                    | Ref                    | <.001             | Ref                   | <.001            |
| Business                   | 1.00 (0.74–1.34)        |                   | 1.10 (0.99–1.22)      |                  |
| Humanitarian service work  | 1.77 (1.13–2.76)        |                   | 0.91 (0.72–1.15)      |                  |
| Research/education         | 1.38 (0.92–2.09)        |                   | 1.05 (0.85–1.29)      |                  |
| VFR                        | 0.83 (0.58–1.20)        |                   | 0.78 (0.57–1.07)      |                  |
| Other                      | 1.24 (0.96–1.59)        |                   | 0.81 (0.66–0.99)      |                  |
| US Census region of clinic site |                  |                  |                       |                  |
| Northeast                  | Ref                    | <.001             | Ref                   | <.001            |
| Midwest                    | 0.12 (0.06–0.26)        |                   | 0.06 (0.02–0.13)      |                  |
| South                      | 2.14 (1.48–3.09)        |                   | 2.47 (1.25–4.90)      |                  |
| West                       | 2.27 (1.77–2.91)        |                   | 3.64 (2.66–4.99)      |                  |
| Type of clinic             |                        |                   |                       |                  |
| Nonacademic center         | Ref                    | .64               | Ref                   | .24              |
| Academic center            | 0.81 (0.32–2.07)        |                   | 1.56 (0.72–3.39)      |                  |
| Survey year                |                        |                   |                       |                  |
| 2009                       | Ref                    | .023              | Ref                   | <.001            |
| Each year after 2009       | 0.88 (0.78–0.99)        |                   | 0.77 (0.73–0.82)      |                  |

Abbreviations: FQ, fluoroquinolone; GTEN, Global TravEpiNet; OR, odds ratio; TD, travelers’ diarrhea; VFR, visiting friends and relatives.

*Adjusted results obtained from regressions that include all variables shown in the table.

*bReference: not traveling to that specific region. Travelers can contribute to >1 region.
for mild TD and antibiotics alone or with loperamide for moderate or severe TD) [6].

Although our findings suggest that clinical practice has been evolving, >70% of GTEN travelers were still prescribed antibiotics in 2018, which is consistent with CDC and ISTM guidelines, which continue to recommend antibiotics as primary treatment for TD [1]. Variability in oral antibiotic prescribing practices on the provider level is well described, and we similarly identified significant variation in clinical practice, even among specialized pretravel providers [28]. Providers at GTEN academic sites were significantly more likely to prescribe antibiotics for TD than providers at nonacademic sites, and prescribing practices also differed among geographic regions within the United States. Despite the heterogeneity in prescribing practices we observed, antibiotics were still widely prescribed by GTEN providers, which is consistent with the frequent antibiotic prescribing described in outpatient settings for other indications [29, 30]. Pretravel providers may choose to prescribe empiric antibiotics so that travelers can avoid seeking medical care while abroad, which may be inappropriate or harmful or include substandard or counterfeit antimicrobial drugs [31–33].

We found significant predictors for the prescribing of antibiotics to travelers, which highlight current clinical practice among experienced travel medicine providers. Travelers with longer trips (≥30 days) were less likely to be prescribed antibiotics than travelers with shorter durations of travel; it is possible that long-term travelers anticipate access to medical care while abroad and thus decline antibiotic prescriptions. We found that GTEN travelers visiting Africa were no more likely to be prescribed antibiotics than those visiting other regions, although travelers to Africa experience a high incidence of TD [4, 34]. VFR travelers were less likely to be prescribed antibiotics at GTEN sites. It is possible that VFR travelers may be less likely to accept pretravel advice despite the higher risk of some illnesses while abroad, that some providers may assume that VFR travelers have adequate access to medical care at the destination, or that providers may fail to offer adequate pretravel advice to VFR travelers [4, 35, 36]. Providers should be aware of potential disparities in pretravel care for VFR travelers, and these data highlight the importance of clinical guidelines to address high-risk groups of travelers.

We also found significant demographic and travel-related associations with prescribing fluoroquinolones relative to azithromycin. Females were less likely than males to be prescribed fluoroquinolones compared with azithromycin, perhaps due to concern for fetal and developmental toxicities with the use of quinolones during pregnancy [37]. Travelers with self-reported macrolide allergies were more likely to receive prescriptions for fluoroquinolones; the opposite trend was observed in travelers with self-reported fluoroquinolone allergies. Travelers visiting Southeast Asia and the Western Pacific were less likely to be prescribed fluoroquinolones than azithromycin compared with those not visiting these regions, suggesting that providers may be increasingly aware of the prevalence of fluoroquinolone-resistant Campylobacter or responding to the 2017 ISTM guidelines [2, 6, 22–24].

We observed significant periods of decline in fluoroquinolone prescribing. The sharp decline observed in 2009 may reflect providers’ response to a frequently cited 2007 study on increasing fluoroquinolone resistance among Campylobacter spp. among travelers visiting Thailand and recommendations suggesting azithromycin as first-line antibiotic treatment [38]. Among travelers to Southeast Asia, the differences in the rates of decline were not significant before and after the release of the 2016 FDA warning and 2017 ISTM guidelines; GTEN providers may have already been avoiding fluoroquinolone prescribing to these travelers. However, fluoroquinolone prescribing among all GTEN travelers declined at a significantly faster rate following the release of the 2016 FDA warning than before, suggesting its potential impact on pretravel clinical practices. These findings support a recently published analysis that reported a 7.6% decrease in in-hospital fluoroquinolone prescribing in July 2016, the month the FDA warning was released, and additional decreases thereafter (risk ratio, 0.89; 95% CI, 0.79–1.01) [39], although other studies have not demonstrated a significant effect of the 2016 FDA warning on outpatient fluoroquinolone prescribing [40, 41]. With the decline in fluoroquinolone prescribing, we observed corresponding increases in azithromycin prescribing, which support ISTM guidelines that recommend azithromycin for moderate to severe TD [6].

Although GTEN is the largest consortium of clinical sites that provide pretravel consultations in the United States, our analysis has limitations. Individuals seeking pretravel advice may be less likely to participate in risky behaviors, and providers may deem that counsel on the risks of TD and use of supportive care is sufficient for these travelers. Patient demographics and antibiotic prescribing practices at GTEN sites may not be generalizable to the general population of US travelers and providers, especially for VFR travelers. Additionally, we could not stratify antibiotic prescribing patterns by the training of GTEN pretravel providers (eg, physician, nurse, pharmacist). As in other GTEN analyses, we categorized travelers’ itineraries by WHO geographic regions, which may not capture the details of TD risk during specific itineraries [25]. Given that the FDA warning and ISTM guidelines occurred within a year of each other, we were unable to discern the individual impact of these 2 public health interventions on antibiotic prescribing practices. Because these data capture antibiotic prescriptions at GTEN sites, our analysis does not include instances when loperamide was prescribed alone or with antibiotics, provider reasons for prescribing patterns, patient preferences, patient refusal of antibiotics, or actual antibiotic use among...
travelers. However, these data regarding prescriber patterns remain vitally important and emphasize the changes in provider decision-making regarding antibiotic prescribing over the past 10 years.

In conclusion, our findings suggest that the prescribing of empiric antibiotics for travelers’ diarrhea has declined significantly over the past 10 years but remains a common clinical practice at pretravel consultations. Specifically, we found that fluoroquinolone prescribing has dramatically declined, especially among travelers visiting Southeast Asia, while azithromycin is now the most frequently prescribed antibiotic for TD. Emerging data on the risks and benefits of antibiotics, recent antimicrobial stewardship efforts, and updated clinical practice guidelines may have contributed to the decline in antibiotic prescribing for TD, especially for fluoroquinolones.

**Supplementary Data**

Supplementary materials are available at Open Forum Infectious Diseases online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

**Acknowledgments**

Members of the Global TravEpiNet Consortium (in alphabetical order).

George M. Abraham, Saint Vincent Hospital (Worcester, MA, USA); Salvador Alvarez, Mayo Clinic (Jacksonville, FL, USA); Vernon Ansdel and Johnnie A. Yates, Travel Medicine Clinic, Kaiser Permanente (Honolulu, HI, USA); Elisha H. Atkins, Chelsea HealthCare Center (Chelsea, MA, USA); Holly K. Birich and Dagmar Vittek, Salt Lake Valley Health Department (Salt Lake, UT, USA); John Cahill, Travel and Immunization Center, St. Luke's-Roosevelt (New York, NY, USA); Lin Chen, Mount Auburn Hospital (Cambridge, MA, USA); Marina Rogova, Bradley A. Connor, New York Center for Travel and Tropical Medicine, Cornell University (New York, NY, USA); Roberta Dismukes, Jessica Fairley, Phyllis Kozarsky, Henry Wu, Emory TravelWell, Emory University (Atlanta, GA, USA); Jeffrey A. Goad and Edith Mirzaian, International Travel Medicine Clinic, University of Southern California (Los Angeles, CA, USA); Stefan Hagmann, and Edith Mirzaian, International Travel Medicine Clinic, University Emory TravelWell, Emory University (Atlanta, GA, USA); Jeffrey A. Goad and Edith Mirzaian, International Travel Medicine Clinic, University of Southern California (Los Angeles, CA, USA); Stefan Hagmann, and Edith Mirzaian, International Travel Medicine Clinic, University Emory TravelWell, Emory University (Atlanta, GA, USA); Jeffrey A. Goad

**References**

1. Connor BA. Preparing international travelers. In: Brunette GW, Némethauser JB, eds. Centers for Disease Control and Prevention Yellow Book. Atlanta: Centers for Disease Control and Prevention, 2019. Available at: https://www.cdc.gov/travel/yellowbook/2020/preparing-international-travelers/travelers-diarrhea. Accessed 17 October 2019.

2. Steffen R, Hill DR, DuPont HL. Traveler’s diarrhea: a clinical review. JAMA 2015; 313:71–80.

3. De Bruyn G, Hahn S, Borwick A. Antibiotic treatment for travelers’ diarrhoea. Cochrane Database Syst Rev 2000; 3:CD002242.

4. Latani T, Maguire JD, Grant EM, et al; ICDPR TravMil Study Group. Epidemiology and self-treatment of travelers’ diarrhea in a large, prospective cohort of department of defense beneficiaries. J Travel Med 2015; 22:152–60.

5. Soonawala D, Vlot JA, Visser LG. Inconvenience due to travelers’ diarrhea: a prospective follow-up study. BMC Infect Dis 2011; 11:322.

6. Siddle MS, Connor BA, Beching NJ, et al. Guidelines for the prevention and treatment of travelers’ diarrhea: a graded expert panel report. J Travel Med 2017; 24:57–74.

7. Lävieri T, Sterne J, Rombo L, Kantele A. Systematic review of lopamidol: no proof of antibiotics being superior to lopamidol in treatment of mild/moderate travellers’ diarrhoea. Travel Med Infect Dis 2016; 14:299–312.

8. Ericsson CD, DuPont HL, Mathewson JJ, et al. Treatment of traveler’s diarrhea with sulfamethoxazole and trimethoprim and lopamidol. JAMA 1990; 263:257–61.

9. Dupont HL, Jiang ZD, Belkind-Gerson J, et al. Treatment of travelers’ diarrhea: randomized trials comparing rifaximin, rifaximin plus loperamide, and loperamide alone. Clin Gastroenterol Hepatol 2007; 5:451–6.

10. Brown KA, Kanahele N, Daneman N, Fisman DN. Meta-analysis of antibiotics and the risk of community-associated Clostridium difficile infection. Antimicrob Agents Chemother 2013; 57:3236–32.

11. Tamma PD, Arcide E, Li DX, et al. Association of adverse events with antibiotic use in hospitalized patients. JAMA Intern Med 2017; 177:1308–15.

12. Schwartz KL, Morris SK. Travel and the spread of drug-resistant bacteria. Curr Infect Dis Rep 2018; 20:29.

13. Centers for Disease Control and Prevention. Antibiotic Resistance Threats in the United States. Atlanta, GA: US Department of Health and Human Services; 2019. Available at: https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf. Accessed 12 December 2019.

14. Frost L, Van Bockel TP, Pires J, et al. Global geographic trends in antimicrobial resistance: the role of international travel. J Travel Med. In press.

15. Mellon G, Turbett SE, Worby C, et al. Acquisition of antibiotic-resistant bacteria by U.S. international travelers. N Engl J Med 2020; 382:1372–4.

16. Arcilla MS, van Haltem HM, Haverkate MR, et al. Import and spread of extended-spectrum β-lactamase-producing Enterobacteriaceae by international travelers (COMBAT study): a prospective, multicentre cohort study. Lancet Infect Dis 2017; 17:57–85.

17. Langford BJ, Schwartz KL. Bringing home unwelcome souvenirs: travel and drug-resistant bacteria. Can Commun Dis Rep 2018; 44:277–82.

18. US Food and Drug Administration. FDA drug safety communication: FDA updates warnings for oral and injectable fluoroquinolone antibiotics due to disabling side effects. 2016. Available at: https://www.fda.gov/media/99425/download. Accessed 17 October 2019.

19. US Food and Drug Administration. FDA drug safety communication: FDA re-inforces safety information about serious low blood sugar levels and mental health.
side effects with fluoroquinolone antibiotics; requires label changes. 2018. Available at: https://www.fda.gov/media/114192/download. Accessed 17 October 2019.

20. US Food and Drug Administration. FDA drug safety communication: FDA warns about increased risk of ruptures or tears in the aorta blood vessel with fluoroquinolone antibiotics in certain patients. 2018. Available at: https://www.fda.gov/media/119532/download. Accessed 17 October 2019.

21. Bennett AC, Bennett CL, Witherspoon BJ, Knopf KB. An evaluation of reports of ciprofloxacin, levofloxacin, and moxifloxacin-association neuropsychiatric toxicities, long-term disability, and aortic aneurysms/dissections disseminated by the Food and Drug Administration and the European Medicines Agency. Expert Opin Drug Saf 2019; 18:1055–63.

22. Hoge CW, Gambel JM, Srijan A, et al. Trends in antibiotic resistance among diarrheal pathogens isolated in Thailand over 15 years. Clin Infect Dis 1998; 26:341–5.

23. Lääveri T, Vilkman K, Pakkanen SH, et al. A prospective study of travellers’ diarrhoea: analysis of pathogen findings by destination in various (sub)tropical regions. Clin Microbiol Infect 2018; 24:908.e9–16.

24. Pandey P, Bodhidatta L, Lewis M, et al. Travelers’ diarrhea in Nepal: an update on the pathogens and antibiotic resistance. J Travel Med 2011; 18:102–8.

25. LaRocque RC, Rao SR, Lee J, et al; Global TravEpiNet Consortium. Global TravEpiNet: a national consortium of clinics providing care to international travelers—analysis of demographic characteristics, travel destinations, and pretravel healthcare of high-risk US international travelers, 2009-2011. Clin Infect Dis 2012; 54:455–62.

26. World Health Organization. World Health Organization regional offices. Available at: https://www.who.int/about/who-we-are/regional-offices. Accessed 2 October 2019.

27. DuPont HL, Steffen R. Use of antimicrobial agents for treatment and prevention of travelers’ diarrhoea in the face of enhanced risk of transient fecal carriage of multi-drug resistant Enterobacteriaceae: setting the stage for consensus recommendations. J Travel Med 2017; 24:57–62.

28. Schwartz KL, Brown KA, Etches J, et al. Predictors and variability of antibiotic prescribing amongst family physicians. J Antimicrob Chemother 2019; 74:2098–105.

29. Brown A, Wong JR, Kandiah S, et al. Inappropriate fluoroquinolone use in academic and non-academic primary care clinics. J Gen Intern Med 2019; 34:2342–4.

30. Fleming-Dutra KE, Hersh AL, Shapiro DJ, et al. Prevalence of inappropriate antibiotic prescriptions among US ambulatory care visits, 2010-2011. JAMA 2016; 315:1864–73.

31. Kelesidis T, Falagas ME. Substandard/counterfeit antimicrobial drugs. Clin Microbiol Rev 2015; 28:443–64.

32. Nayyar GML, Attaran A, Clark JP, et al. Responding to the pandemic of falsified medicines. Am J Trop Med Hyg 2015; 92:113–8.

33. Wyss MN, Steffen R, Dhupdale NY, et al. Management of travelers’ diarrhea by local physicians in tropical and subtropical countries—a questionnaire survey. J Travel Med 2009; 16:186–90.

34. Leder K, Torresi J, Libman MD, et al; GeoSentinel Surveillance Network. GeoSentinel surveillance of illness in returned travelers, 2007-2011. Ann Intern Med 2013; 158:456–68.

35. Centers for Disease Control and Prevention. Traveler advice: visiting friends or relatives in a foreign country. 2016. Available at: https://wwwnc.cdc.gov/travel/page/vfr. Accessed 28 October 2019.

36. Lammert SM, Rao SR, Jentes ES, et al. Refusal of recommended travel-related vaccines among U.S. international travellers in Global TravEpiNet. J Travel Med 2016; 24.

37. Padberg S, Wacker E, Meister R, et al. Observational cohort study of pregnancy outcome after first-trimester exposure to fluoroquinolones. Antimicrob Agents Chemother 2014; 58:4392–8.

38. Tribble DR, Sanders JW, Pang LW, et al. Traveler’s diarrhea in Thailand: randomized, double-blind trial comparing single-dose and 3-day azithromycin-based regimens with a 3-day levofloxacin regimen. Clin Infect Dis 2007; 44:338–46.

39. Yarrington ME, Anderson DJ, Dodds Ashley E, et al. Impact of FDA black box warning on fluoroquinolone and alternative antibiotic use in Southeastern US hospitals. Infect Control Hosp Epidemiol 2019; 40:1297–300.

40. Bratsman A, Mathias K, Laubscher R, et al. Outpatient fluoroquinolone prescribing patterns before and after US FDA boxed warning. Pharmacoeconom Drug Saf 2020; 29:701–7.

41. Cowart K, Worley M, Rouby NE, Sando K. Evaluation of FDA boxed warning on prescribing patterns of fluoroquinolones for uncomplicated urinary tract infections. Ann Pharmacother 2019; 53:1192–9.